A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

Clinical trial NCT01853878 · COMPLETED

Trial details

NCT number: NCT01853878
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer, Non-Small Cell

Start date: 2013-06-12
Primary completion: 2016-08-24
Enrollment: 137

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.